Trial · NCT01238848
Efficacy of Nebulized Hypertonic Saline in the Treatment of Acute Bronchiolitis
NCT01238848, Not applicable, Completed, Hospital General de Niños Pedro de Elizalde; results first posted 2012-08-17
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Efficacy of Nebulized Hypertonic Saline in the Treatment of Acute Bronchiolitis. Trials, record NCT01238848. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01238848
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy of Nebulized Hypertonic Saline in the Treatment of Acute Bronchiolitis
- NCT number
- NCT01238848
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 82 participants, actual
- Lead sponsor
- Hospital General de Niños Pedro de Elizalde
- Conditions
- Bronchiolitis
- Interventions
- Hypertonic saline, Normal saline
- First posted
- 2010-11-11
- Last updated
- 2017-02-10
- Results first posted
- 2012-08-17
- Limitations and caveats
- The initially estimated sample size was not achieved
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Hospitalization Days | Participants will be followed for the duration of hospitalization, an expected average of 4 days | hospitalization days |
| Secondary | Length of Oxygen Use | Participants will be followed for the duration of hospitalization, an expected average of 4 days | Length of oxygen use (days) |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| SECONDARY | Length of Oxygen Use | Participants will be followed for the duration of hospitalization, an expected average of 4 days | days | MEDIAN | |
| PRIMARY | Hospitalization Days | Participants will be followed for the duration of hospitalization, an expected average of 4 days | days | MEDIAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Length of Oxygen Use | Hypertonic | 4 | Standard Deviation 3.4 | days | |
| Length of Oxygen Use | Normal | 3.22 | Standard Deviation 2.3 | days | |
| Hospitalization Days | Hypertonic | 5.8 | Standard Deviation 2.7 | days | |
| Hospitalization Days | Normal | 5.47 | Standard Deviation 2.1 | days |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Hypertonic | 50 | |
| Overall Study | STARTED | Normal | 50 | |
| Overall Study | COMPLETED | Hypertonic | 37 | |
| Overall Study | COMPLETED | Normal | 45 | |
| Overall Study | NOT COMPLETED | Hypertonic | 13 | |
| Overall Study | NOT COMPLETED | Normal | 5 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Hypertonic | ||
| Total, all-cause mortality | Normal | ||
| Total, other adverse events | Hypertonic | 0 | 50 |
| Total, other adverse events | Normal | 0 | 50 |
| Total, serious adverse events | Hypertonic | 0 | 50 |
| Total, serious adverse events | Normal | 0 | 50 |
Source ClinicalTrials.gov
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Hypertonic vs Normal: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01238848
GET https://conductscience.org/api/trials/v1/NCT01238848/registered